J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522338-30-00

Enrollment

Registered

2026-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

The proportion of participants who achieve clinical remission with mMS at Week 12

Interventions

DRUGMirikizumab

DRUGPlacebo to match LY

DRUGPlacebo to Mirikizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of participants who achieve clinical remission with mMS at Week 12	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 21, 2026